Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GlaukosGKOS -1.07%79 Net Cash per Share is $0.82 as of Jun. 2026, which is 98% below its 10-year median of 51.20. GuruFocus rates GKOS with a GF Score™ of 79/100 and a GF Value™ of $147.05 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 302 Medical Devices & Instruments companies, Glaukos ranks worse than 97.02% on this metric.
The historical rank and industry rank for Glaukos's Net Cash per Share or its related term are showing as below:
GKOS'
s Price-to-Net-Cash Range Over the Past 10 Years
Min: 9.72 Med: 51.2 Max: 1628.5
Current: 203.32
During the past 13 years, the highest Price-to-Net-Cash Ratio of Glaukos was 1628.50. The lowest was 9.72. And the median was 51.20.
GKOS's Price-to-Net-Cash is ranked worse than 97.02% of 302
companies
in the Medical Devices & Instruments industry
Industry Median: 7.605
vs GKOS: 203.32
Glaukos (NYSE:GKOS) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Glaukos Net Cash per Share Related Terms
Glaukos Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Glaukos's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GKOS vs BRKR, BIO, GMED: Net Cash per Share Comparison
For the Medical Devices subindustry, Glaukos's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glaukos Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Glaukos's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Glaukos's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Glaukos's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glaukos (GKOS) has a Net Cash per Share of $0.82 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Glaukos and its competitors. This is 98% below median its historical median of 51.20. Over the past decade, Glaukos' Net Cash per Share has ranged from 9.72 to 1,628.50. According to the industry distribution chart, Glaukos ranks #293 out of 302 companies in the Medical Devices & Instruments industry, placing it in the top 97%.
Is Glaukos' Net Cash per Share too high?
Glaukos' current Net Cash per Share of $0.82 is 98% below median its 10-year median of 51.20. Over the past 10 years, this metric has ranged from a low of 9.72 to a high of 1,628.50. The Medical Devices & Instruments industry median Net Cash per Share is 7.61. Glaukos' value of $0.82 is 89.2% below this industry median. Based on the distribution chart, Glaukos ranks #293 out of 302 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Glaukos has a GF Score™ of 79/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glaukos' Net Cash per Share compare to BRKR and BIO?
According to the Medical Devices & Instruments industry distribution chart, Glaukos ranks #293 out of 302 companies for Net Cash per Share. This places Glaukos in the lower half of its industry. The industry median Net Cash per Share is 7.61. Glaukos' value of $0.82 is 89.2% below this benchmark. Historically, Glaukos' own Net Cash per Share has ranged from 9.72 to 1,628.50 over the past decade. While the company's 10-year median is 51.20 vs. the industry median of 7.61, Glaukos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 7.61, based on 302 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glaukos's current Net Cash per Share of $0.82 is 89.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Glaukos and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 7.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glaukos's current Net Cash per Share is $0.82, which is 98% below median its own 10-year median of 51.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glaukos stock overvalued right now?
Based on GuruFocus' analysis, Glaukos (GKOS) is currently considered Modestly Overvalued. The stock's GF Value™ is $147.05, compared to a current price of $166.72 — trading 13.4% above its estimated fair value. The current Net Cash per Share is $0.82, which is 98% below median its 10-year median of 51.20 and 89.2% below the Medical Devices & Instruments industry median of 7.61. Glaukos' overall GF Score™ is 79/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Glaukos (GKOS), the current Net Cash per Share is $0.82 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glaukos (GKOS) Overvalued in 2026?
Based on GuruFocus' analysis, Glaukos stock appears to be overvalued.
The current stock price of $166.72 is trading 13.4% above its estimated GF Value™ of $147.05.
GuruFocus considers Glaukos to be Modestly Overvalued.
Key valuation signals for GKOS:
Net Cash per Share: $0.82 (98% below median its 10-year median of 51.20)
GF Value™: $147.05 vs. price of $166.72 (13.4% above fair value)
Industry Position: 89.2% below the Medical Devices & Instruments median (#293 of 302)
No single metric tells the full story. See the GKOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
79GF Score
Get the complete analysis for GKOS
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GKOS has been successfully added to your 
